AI in Healthcare

The landscape of drug discovery is undergoing a monumental shift. Today, Bristol Myers Squibb announced an expanded collaboration with NVIDIA, deploying the most powerful AI infrastructure in life sciences to accelerate the development of new medicines. This isn't just about speed; it's about fundamentally reshaping how research is conducted, embracing a 'hybrid intelligence' model where AI co-scientists augment human expertise. By leveraging advanced NVIDIA DGX SuperPOD systems and training next-generation foundation models on proprietary data, the goal is to increase the probability of discovering and advancing the most promising drug candidates. What are the most significant ethical considerations when AI takes on such a central role in pharmaceutical innovation? How do we ensure human oversight remains paramount while maximizing AI's transformative potential? Source: Bristol Myers Squibb Press Release, "Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA," published July 20, 2026. https://news.bms.com/news/corporate-news/2026/Bristol-Myers-Squibb-to-Build-the-Most-Powerful-AI-Factory-in-Life-Sciences-with-NVIDIA/default.aspx View and join any or all of our communities — AI, quantum, and real estate: https://alex-companies.com/linkedin/groups If there's an AI, quantum, or real estate community you'd like to see us convene, tell us — this portfolio grows by request. MIT, Nvidia, Google and IBM-Trained. Cross Domain-Expert. Quantum AI Educator. Solepoint (Facts Already Defined) Strategic Practitioner. Real Estate Intelligence Leader. VUI Native AI Cloud Architect. AI Certifications Development. George Arnold Alexander III Director, ALEX Companies Associate Broker, Alexander Tiffany Southwest, LLC +1 713.918.9951 · [email protected]